These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1557421)

  • 1. A growth-regulated protease activity that is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor.
    Billings PC; Habres JM
    Proc Natl Acad Sci U S A; 1992 Apr; 89(7):3120-4. PubMed ID: 1557421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human fibroblasts contain a proteolytic activity which is inhibited by the Bowman-Birk protease inhibitor.
    Billings PC; Habres JM; Liao DC; Tuttle SW
    Cancer Res; 1991 Oct; 51(20):5539-43. PubMed ID: 1913672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential intracellular target proteins of the anticarcinogenic Bowman Birk protease inhibitor identified by affinity chromatography.
    Billings PC; St Clair W; Owen AJ; Kennedy AR
    Cancer Res; 1988 Apr; 48(7):1798-802. PubMed ID: 3280120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A proteolytic activity in a human breast cancer cell line which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor.
    Moy LY; Billings PC
    Cancer Lett; 1994 Oct; 85(2):205-10. PubMed ID: 7954338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a soluble enzyme from C3H/10T1/2 cells which is inhibited by the Bowman-Birk proteinase inhibitor.
    Fagan JM; Waxman L
    Biochem Biophys Res Commun; 1991 Aug; 178(3):856-61. PubMed ID: 1872865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal epithelial cells contain a high molecular weight protease subject to inhibition by anticarcinogenic protease inhibitors.
    Habres JM; Billings PC
    Cancer Lett; 1992 Apr; 63(2):135-42. PubMed ID: 1562990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A serine protease activity in C3H/10T1/2 cells that is inhibited by anticarcinogenic protease inhibitors.
    Billings PC; Carew JA; Keller-McGandy CE; Goldberg AL; Kennedy AR
    Proc Natl Acad Sci U S A; 1987 Jul; 84(14):4801-5. PubMed ID: 3299374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteases occurring in the cell membrane: a possible cell receptor for the Bowman-Birk type of protease inhibitors.
    Yavelow J; Caggana M; Beck KA
    Cancer Res; 1987 Mar; 47(6):1598-601. PubMed ID: 3545448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolytic activities of mouse sarcoma 180 cells that are inhibited by Bowman-Birk and Kunitz protease inhibitors.
    Chu SC; Chou FP; Liu JY; Lin LJ; Hsieh YS
    Biochem Mol Biol Int; 1997 Aug; 42(5):965-75. PubMed ID: 9285064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Internalisation of the Bowman-Birk protease inhibitor by intestinal epithelial cells.
    Billings PC; Brandon DL; Habres JM
    Eur J Cancer; 1991; 27(7):903-8. PubMed ID: 1834126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of 3-methylcholanthrene-induced cellular transformation by timed administration of the Bowman-Birk protease inhibitor.
    St Clair WH
    Carcinogenesis; 1991 May; 12(5):935-7. PubMed ID: 2029760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the Bowman-Birk protease inhibitor on survival of fibroblasts and cancer cells exposed to radiation and cis-platinum.
    Kennedy CW; Donahue JJ; Wan XS
    Nutr Cancer; 1996; 26(2):209-17. PubMed ID: 8875558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase.
    Ware JH; Wan XS; Rubin H; Schechter NM; Kennedy AR
    Arch Biochem Biophys; 1997 Aug; 344(1):133-8. PubMed ID: 9244390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological significance of polymorphism in legume protease inhibitors from the Bowman-Birk family.
    Clementea A; Domoney C
    Curr Protein Pept Sci; 2006 Jun; 7(3):201-16. PubMed ID: 16787260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoconjugates of soybean Bowman-Birk protease inhibitor as targeted antitumor polymeric agents.
    Gladysheva IP; Moroz NA; Karmakova TA; Nemtsova ER; Yakubovskaya RI; Larionova NI
    J Drug Target; 2001; 9(5):303-16. PubMed ID: 11770701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1.
    Chen YW; Huang SC; Lin-Shiau SY; Lin JK
    Carcinogenesis; 2005 Jul; 26(7):1296-306. PubMed ID: 15746161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteases, protease inhibitors and radiation carcinogenesis.
    Kennedy AR
    Int J Radiat Biol; 2023; 99(6):882-890. PubMed ID: 34325613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative growth control of osteosarcoma cell by Bowman-Birk protease inhibitor from soybean; involvement of connexin 43.
    Saito T; Sato H; Virgona N; Hagiwara H; Kashiwagi K; Suzuki K; Asano R; Yano T
    Cancer Lett; 2007 Aug; 253(2):249-57. PubMed ID: 17343982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiapoptotic activity of the Bowman-Birk inhibitor can be attributed to copurified phospholipids.
    Foehr MW; Tomei LD; Goddard JG; Pemberton PA; Bathurst IC
    Nutr Cancer; 1999; 34(2):199-205. PubMed ID: 10578488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bowman-Birk inhibitor suppresses production of superoxide anion radicals in differentiated HL-60 cells.
    Ware JH; Wan XS; Kennedy AR
    Nutr Cancer; 1999; 33(2):174-7. PubMed ID: 10368813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.